Cargando…

Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis

BACKGROUND: Muscle-invasive bladder cancer (MIBC) is a heterogeneous disease, and gene expression profiling has identified several molecular subtypes with distinct biological and clinicopathological characteristics. While MIBC subtyping has primarily been based on messenger RNA (mRNA), long non-codi...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Jong, Joep J., Liu, Yang, Robertson, A. Gordon, Seiler, Roland, Groeneveld, Clarice S., van der Heijden, Michiel S., Wright, Jonathan L., Douglas, James, Dall’Era, Marc, Crabb, Simon J., van Rhijn, Bas W. G., van Kessel, Kim E. M., Davicioni, Elai, Castro, Mauro A. A., Lotan, Yair, Zwarthoff, Ellen C., Black, Peter C., Boormans, Joost L., Gibb, Ewan A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796434/ https://www.ncbi.nlm.nih.gov/pubmed/31619281 http://dx.doi.org/10.1186/s13073-019-0669-z

Ejemplares similares

Elevated Derived Neutrophil-to-Lymphocyte Ratio Corresponds With Poor Outcome in Patients Undergoing Pre-Operative Chemotherapy in Muscle-Invasive Bladder Cancer
por: van Kessel, Kim E.M., et al.
Publicado: (2016)

Indications for and transitioning to secondary treatment while on active surveillance for prostate cancer
por: Glass, Allison S., et al.
Publicado: (2018)

Active Surveillance for Intermediate Risk Prostate Cancer
por: Dall'Era, Marc A., et al.
Publicado: (2016)

A showcase study on personalized in silico drug response prediction based on the genetic landscape of muscle invasive bladder cancer
por: Krentel, Friedemann, et al.
Publicado: (2021)

Active Surveillance for Localized Prostate Cancer – Current Practices and Recommendations
por: Wu, Jennifer N., et al.
Publicado: (2010)

Defining the Optimal Management Strategy for Small Renal Masses
por: Dall’Era, Marc, et al.
Publicado: (2021)

Limited Funds for Bladder Cancer Research and What Can We Do About It
por: Boormans, Joost L., et al.
Publicado: (2016)

Active surveillance for prostate cancer
por: Dall’Era, Marc A., et al.
Publicado: (2018)

Patient-Centered Outcomes Research Institute (PCORI) multisite project to develop treatment decision aids for racial/ethnic minorities with lupus nephritis
por: Yazdany, Jinoos, et al.
Publicado: (2014)

Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma
por: Tsai, Harrison K., et al.
Publicado: (2017)

A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable
por: van Kessel, Kim E. M., et al.
Publicado: (2017)

Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma
por: Alshalalfa, Mohammed, et al.
Publicado: (2019)

Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients
por: Alshalalfa, Mohammed, et al.
Publicado: (2017)

Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome
por: Dall'Era, Maria, et al.
Publicado: (2015)

The Metastatic Risk of Renal Cell Carcinoma by Primary Tumor Size and Subtype
por: Monda, Steven M., et al.
Publicado: (2023)

Preliminary population-based incidence and prevalence estimates of systemic lupus erythematosus: the California Lupus Surveillance Project
por: Dall'Era, Maria C, et al.
Publicado: (2014)

Down-staging (<pT2) of urothelial cancer at cystectomy after the diagnosis of detrusor muscle invasion (pT2) at diagnostic transurethral resection (TUR): is prediction possible?
por: Beukers, Willemien, et al.
Publicado: (2012)

Transcriptome-Wide Detection of Differentially Expressed Coding and Non-Coding Transcripts and Their Clinical Significance in Prostate Cancer
por: Erho, Nicholas, et al.
Publicado: (2012)

The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder
por: van Doeveren, Thomas, et al.
Publicado: (2020)

Validation study of a computer-based open surgical trainer: SimPraxis(®) simulation platform
por: Tran, Linh N, et al.
Publicado: (2013)

A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial
por: Tamirou, Farah, et al.
Publicado: (2015)

Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma
por: D’Andrea, David, et al.
Publicado: (2020)

Evolving transcriptomic fingerprint based on genome‐wide data as prognostic tools in prostate cancer
por: Alshalalfa, Mohammed, et al.
Publicado: (2015)

Novel lncRNAs Co-Expression Networks Identifies LINC00504 with Oncogenic Role in Luminal A Breast Cancer Cells
por: Mathias, Carolina, et al.
Publicado: (2021)

Differential expression of CD10 in prostate cancer and its clinical implication
por: Dall'Era, Marc A, et al.
Publicado: (2007)

Schlafen 12 Slows TNBC Tumor Growth, Induces Luminal Markers, and Predicts Favorable Survival
por: Singhal, Sandeep K., et al.
Publicado: (2023)

Prospective bladder cancer infrastructure for experimental and observational research on bladder cancer: study protocol for the ‘trials within cohorts’ study ProBCI
por: Richters, Anke, et al.
Publicado: (2021)

Development of a predictive model for stromal content in prostate cancer samples to improve signature performance
por: Boufaied, Nadia, et al.
Publicado: (2019)

Mortality Among Minority Populations with Systemic Lupus Erythematosus, Including Asian and Hispanic/Latino Persons — California, 2007–2017
por: Gianfrancesco, Milena A., et al.
Publicado: (2021)

Differential regulation of the interferon response in systemic lupus erythematosus distinguishes patients of Asian ancestry
por: Rector, Ian, et al.
Publicado: (2023)

Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA
por: Collins, C E, et al.
Publicado: (2016)

Estimates of Responsiveness, Minimally Important Differences, and Patient Acceptable Symptom State in Five Patient‐Reported Outcomes Measurement Information System Short Forms in Systemic Lupus Erythematosus
por: Katz, Patricia, et al.
Publicado: (2019)

Effect of Neoadjuvant Chemotherapy on Renal Function following Radical Cystectomy: Is there a Meaningful Impact?
por: Chandrasekar, Thenappan, et al.
Publicado: (2016)

Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance
por: Herlemann, Annika, et al.
Publicado: (2019)

PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assays
por: de Jong, Joep J., et al.
Publicado: (2021)

Prostate Cancer Tumor Volume and Genomic Risk
por: Ramaswamy, Ashwin, et al.
Publicado: (2023)

FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy
por: Kompier, Lucie C., et al.
Publicado: (2010)

A glimpse into the future of systemic lupus erythematosus
por: Aringer, Martin, et al.
Publicado: (2022)

On the theory of the "luminous" electrons
por: Sokolov, A A
Publicado: (1956)

Incongruence in number–luminance congruency effects
por: Gebuis, Titia, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_03lhct8gk3a6jh5jtvfjq8ahiq